Hospital
Prime Healthcare Services-Providence, LLC
Prime Healthcare Services-Providence, LLC was paid $2.14M by Medicaid between Jan 2018 and Nov 2024, across 94 billing codes. Its largest line is 99283, emergency room visit (moderate) — 27% of everything it billed.
33Billing provider infoPRIME HEALTHCARE SERVICES-PROVIDENCE, LLC
KANSAS CITY, KS 66112
KANSAS CITY, KS 66112
33aNPI1528301900assigned 04/03/2013
33bProvider typeGeneral Acute Care Hospital
28Total paid$2.14M
24GClaims99,389
24DCodes billed94
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kansas
Rank by total paid#13 of 48
Median peer was paid$461K
This provider vs. median4.6×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official DOAN, CHRISTOPHER controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 18,592 | $524K | |
| 2019 | 14,692 | $330K | |
| 2020 | 9,618 | $182K | |
| 2021 | 8,027 | $147K | |
| 2022 | 13,917 | $278K | |
| 2023 | 23,920 | $421K | |
| 2024incomplete | 10,623 | $255K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 27% | 12,388 | 11,476 | $582K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 22% | 9,495 | 8,567 | $475K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 17% | 7,444 | 6,494 | $371K |
| 87428 | 3.5% | 1,998 | 1,810 | $75K | |
| 80053 | Comprehensive metabolic panel | 3.5% | 7,258 | 6,137 | $75K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 2.7% | 2,703 | 2,270 | $59K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.5% | 9,934 | 8,415 | $54K |
| 81001 | 1.9% | 7,116 | 6,326 | $41K | |
| 81025 | 1.6% | 3,326 | 2,903 | $34K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 2,457 | 2,013 | $31K |
| 71045 | Radiologic examination, chest; single view | 1.4% | 2,124 | 1,828 | $31K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.4% | 1,754 | 849 | $30K |
82 more codes
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.4% | 334 | $30K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.1% | 415 | $24K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.1% | 978 | $24K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 1,039 | $20K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 268 | $19K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,836 | $16K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 137 | $11K |
| 84484 | <1% | 1,733 | $11K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 747 | $10K |
| 83690 | <1% | 1,839 | $9K | |
| G0378 | Hospital observation service, per hour | <1% | 383 | $9K |
| 36415 | Collection of venous blood by venipuncture | <1% | 10,355 | $8K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 204 | $7K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 137 | $7K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 318 | $6K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 694 | $6K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 96 | $4K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 124 | $4K |
| 62323 | <1% | 27 | $3K | |
| 83735 | <1% | 439 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 64 | $3K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 64 | $3K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 298 | $3K |
| 85610 | <1% | 525 | $3K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 56 | $3K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 48 | $2K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 74 | $2K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 36 | $2K |
| 80076 | <1% | 70 | $2K | |
| 87070 | <1% | 191 | $2K | |
| 76801 | <1% | 30 | $2K | |
| 83880 | <1% | 127 | $2K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 28 | $2K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 93 | $2K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 27 | $2K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 88 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 131 | $1K |
| 85730 | <1% | 365 | $1K | |
| 97597 | <1% | 19 | $994.49 | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 12 | $986.07 |
| 97162 | <1% | 16 | $766.98 | |
| 82553 | <1% | 57 | $714.44 | |
| 87420 | <1% | 55 | $663.91 | |
| 73610 | <1% | 26 | $514.75 | |
| 87807 | <1% | 34 | $497.72 | |
| 87186 | <1% | 37 | $456.30 | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 29 | $427.17 |
| 81003 | <1% | 415 | $415.02 | |
| 73630 | <1% | 18 | $414.53 | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 275 | $406.08 |
| G0379 | Direct admission of patient for hospital observation care | <1% | 313 | $391.23 |
| 87077 | <1% | 42 | $360.32 | |
| 96376 | <1% | 28 | $355.50 | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 544 | $292.27 |
| 84702 | <1% | 26 | $274.90 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 72 | $274.71 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 455 | $256.03 |
| 87081 | <1% | 36 | $224.86 | |
| Q0111 | Wet mounts, including preparations of vaginal, cervical or skin specimens | <1% | 40 | $197.78 |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 17 | $181.13 |
| 83605 | <1% | 35 | $171.82 | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 218 | $168.74 |
| 82962 | <1% | 47 | $163.87 | |
| 85379 | <1% | 16 | $142.95 | |
| J1010 | Injection, methylprednisolone acetate, 1 mg | <1% | 214 | $128.91 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 26 | $100.02 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 414 | $97.41 |
| 86901 | <1% | 14 | $73.40 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,988 | $62.08 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 89 | $47.34 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 138 | $45.46 |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 28 | $35.16 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 60 | $27.12 |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 140 | $8.57 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 26 | $5.99 |
| 85007 | <1% | 33 | $5.28 | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 16 | $2.44 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | <1% | 426 | $1.91 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 29 | $1.25 |
| J2704 | Injection, propofol, 10 mg | 0% | 149 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 289 | $0.00 |
| Q0144 | Azithromycin dihydrate, oral, capsules/powder, 1 gram | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDOAN, CHRISTOPHER (MANAGING ASSOCIATE GENERAL COUNSEL)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.